- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04332848
Susceptibility Testing Guided Versus Empirical Therapy for Refractory H. Pylori Infection
Comparison of Susceptibility Testing Guided Versus Empirical Therapy for the Third-line Eradication of H. Pylori- a Multicenter Randomized Trial
Aim: Therefore, we aimed to
- compare the efficacy of susceptibility testing guided therapy vs. empirical therapy in the third-line eradication for refractory H. pylori infection
- assess the long-term impact of eradication therapy on the antibiotic resistance and microbiota of the gut flora and the metabolic factors.
Methods: This will be a multi-center, open labeled trial
Patients: 360 patients with failure to H. pylori eradication for at least two times will be enrolled Determination of antibiotic resistance of H. pylori:
Agar dilution test will be used to determine the minimum inhibitory concentrations of levofloxacin, tetracycline, rifabutin, and clarithromycin to guide the selection of antibiotics.
Treatment regimens and assignment: Eligible patients will be randomized to receive either one of the treatments (A) Susceptibility testing guided therapy or (B) Empirical therapy
Outcome Measurement:
Primary End Point: Eradication rate will be evaluated according to Intent-to-treat (ITT) analyses.
Secondary End Point: 1. Eradication rate according to per protocol analysis (PP analysis); 2. Frequency of adverse effects.
Study Overview
Status
Conditions
Study Type
Enrollment (Anticipated)
Phase
- Phase 4
Contacts and Locations
Study Contact
- Name: Mei-Jyh Chen
- Phone Number: 66280 886-2-23123456
- Email: migichen@ntuh.gov.tw
Study Contact Backup
- Name: Yu-Chun Huang
- Email: nneder34@gmail.com
Study Locations
-
-
-
Taipei, Taiwan, 10002
- Recruiting
- National Taiwan University Hospital
-
Contact:
- Mei-Jyh Chen, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion criteria
- Adult (equal or greater than 20 years old) patients who failed from at least two eradication therapies for H. pylori infection will be enrolled.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: (B) Empirical therapy
choose antibiotics according to drug history
|
Empirical therapy Based on drug history: Levofloxacin sequential therapy or bismuth quadruple therapy (10 or 14 days) or rifabutin triple therapy or concomitant therapy
|
Active Comparator: (A) Susceptibility testing guided therapy
choose antibiotics according to susceptibility testing
|
Susceptibility testing guided therapy Based on susceptibility test: Levofloxacin sequential therapy or bismuth quadruple therapy (10 or 14 days) or rifabutin triple therapy or concomitant therapy
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The primary outcome is the eradication rate in the third treatment according to intention-to treat (ITT) analysis.
Time Frame: 6 weeks
|
Eradication rate will be determined by urea breath test at least 6 weeks after completion of treatment.
|
6 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Adverse effects
Time Frame: 2 weeks
|
A standard interview and questionaire will be used to assess the adverse effects.
|
2 weeks
|
Collaborators and Investigators
Investigators
- Principal Investigator: Mei-Jyh Chen, MD, National Taiwan University Hospital
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 202001085MINB
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Helicobacter Pylori Infection
-
Bangabandhu Sheikh Mujib Medical University, Dhaka...RecruitingHelicobacter Pylori Infection | Helicobacter Pylori EradicationBangladesh
-
Shandong UniversityRecruitingHelicobacter Pylori Infection | Patient Education | Helicobacter Pylori EradicationChina
-
Shandong UniversityCompletedHelicobacter Pylori Infection Helicobacter Pylori Eradication Patient EducationChina
-
Shanghai Jiao Tong University School of MedicineCompletedCure Rate of Helicobacter Pylori InfectionChina
-
Seoul National University Bundang HospitalRecruitingHelicobacter Pylori Infection | Helicobacter Pylori 23S rRNA Clarithromycin Resistance Mutation | Helicobacter Pylori Associated Gastrointestinal Disease | Helicobacter Pylori Infection, Susceptibility toKorea, Republic of
-
The First Affiliated Hospital of Nanchang UniversityUnknownBacterial Infection Due to Helicobacter Pylori (H. Pylori) | Eradication Therapy of Helicobacter Pylori | Detection of Helicobacter PyloriChina
-
Tanta UniversityNot yet recruitingPersistent Helicobacter Pylori InfectionEgypt
-
Nanjing First Hospital, Nanjing Medical UniversityCompletedHelicobacter Pylori 23S rRNA/gyrA Gene Mutation Detection Kit (Fluorescence PCR Fusion Curve Method)Helicobacter Pylori Infection | Helicobacter Pylori gyrA Levofloxacin Resistance Mutation | Fecal Drug Resistance Gene Detection | Helicobacter Pylori Infection, Susceptibility toChina
-
Kaohsiung Veterans General Hospital.Kaohsiung Medical University Chung-Ho Memorial HospitalCompletedHelicobacter Pylori InfectionTaiwan
-
National Taiwan University HospitalCompleted
Clinical Trials on ET
-
Menoufia UniversityAlexandria UniversityCompleted
-
Universidad de ZaragozaUniversity of ValladolidCompleted
-
University of Wisconsin, MadisonNational Heart, Lung, and Blood Institute (NHLBI)RecruitingChronic Conditions, MultipleUnited States
-
Centre Hospitalier Universitaire, AmiensRecruitingFunctional Magnetic Resonance Imaging | ASD | Social Cognition | Eye Tracking | Joint AttentionFrance
-
Vyaire MedicalM.D. Anderson Cancer CenterCompleted
-
Novartis PharmaceuticalsRecruiting
-
Institute of Hematology & Blood Diseases Hospital...EdiGene Inc.; The Affiliated Hospital Of Guizhou Medical University; Zunyi Medical...Active, not recruitingTransfusion Dependent Beta-ThalassaemiaChina
-
Children's Hospital of PhiladelphiaAnesthesia Patient Safety FoundationCompletedSurgery | Anesthesia, EndotrachealUnited States, Australia
-
EdiGene (GuangZhou) Inc.PLA 923 HospitalActive, not recruitingTransfusion Dependent Beta-ThalassaemiaChina